Mounjaro Maintenance Dose — Long-Term Titration Guide

Mounjaro Maintenance Dose — Long-Term Titration Guide

Research from the SURMOUNT clinical trial program found that patients who titrated to 10mg or 15mg weekly Mounjaro (tirzepatide) demonstrated 15.7% and 20.9% mean body weight reduction respectively at 72 weeks. Compared to just 12.9% at the 5mg dose. The difference isn't marginal. It's the gap between meaningful metabolic reversal and partial response. Yet fewer than 40% of patients in real-world practice ever reach the 10mg threshold, often because prescribers frame 5mg as the maintenance dose when it's actually the mid-point of the titration schedule.

Our team has guided hundreds of patients through Mounjaro titration protocols. The gap between doing it right and doing it wrong comes down to three things most patient guides never mention: understanding that maintenance dose is individualised, recognising plateau as a titration signal rather than a stopping point, and knowing the biological markers that indicate you've reached your true therapeutic ceiling.

What is the Mounjaro maintenance dose?

The Mounjaro maintenance dose is the highest weekly tirzepatide dose a patient can tolerate without persistent adverse effects while achieving sustained metabolic improvement. Ranging from 5mg to 15mg weekly depending on individual response. Clinical protocols define maintenance as the dose that produces stable weight reduction (≤1% body weight fluctuation monthly), improved glycaemic control if diabetic, and resolution of gastrointestinal side effects after the initial 4–8 week adaptation period.

The term 'maintenance dose' is frequently misunderstood. It doesn't refer to a standardised endpoint. It's the dose where further titration no longer improves outcomes or introduces intolerable side effects. For some patients that's 5mg weekly; for others it's 15mg. The FDA-approved titration schedule for Mounjaro begins at 2.5mg weekly, increases to 5mg after four weeks, then allows escalation to 7.5mg, 10mg, 12.5mg, and finally 15mg at four-week intervals based on clinical response. Maintenance is wherever that ladder stops producing benefit. This article covers the biological rationale behind dose escalation, how to identify your true maintenance threshold, what plateau patterns signal the need for titration versus dose stability, and the specific metabolic markers that indicate you've optimised your protocol without over-titrating.

Understanding Tirzepatide's Dose-Response Curve

Tirzepatide operates as a dual GIP and GLP-1 receptor agonist. Meaning it activates both glucose-dependent insulinotropic polypeptide receptors and glucagon-like peptide-1 receptors simultaneously. This dual mechanism explains why Mounjaro's dose-response curve is steeper than single-agonist GLP-1 medications like semaglutide. GIP receptor activation enhances insulin secretion and shifts adipocyte metabolism toward lipolysis, while GLP-1 receptor engagement slows gastric emptying and suppresses appetite signaling through the hypothalamus.

The SURPASS-2 trial published in The New England Journal of Medicine demonstrated that tirzepatide's glucose-lowering effect scales almost linearly with dose. Patients on 15mg weekly achieved A1C reductions of 2.46% from baseline compared to 1.87% at 5mg weekly. The weight loss differential is even more pronounced: 15mg produced mean body weight reduction of 12.4kg versus 7.6kg at 5mg over 40 weeks. These aren't trivial differences. They represent the metabolic gap between reversal-level intervention and partial response.

What this means for maintenance dosing: if you plateau at 5mg. Weight stable for six consecutive weeks despite continued adherence to dietary structure. And your A1C hasn't normalised or you're carrying >20% excess body weight, you haven't reached your maintenance dose. You've reached the dose where further benefit requires titration. The ceiling for most patients is constrained by tolerability, not efficacy. GI side effects. Nausea, vomiting, diarrhoea. Peak during each dose escalation and resolve within four to eight weeks as receptor density in the gut adapts. Stopping at 5mg because of transient nausea during week six is abandoning 40–60% of the medication's potential metabolic impact.

The Standard Titration Schedule vs Real-World Maintenance

The FDA-approved Mounjaro titration protocol follows a structured four-week step-up: start at 2.5mg weekly for four weeks, increase to 5mg weekly for four weeks, then optionally escalate to 7.5mg, 10mg, 12.5mg, or 15mg at four-week intervals. The maximum approved dose is 15mg weekly. This schedule exists to mitigate GI adverse events by allowing gradual receptor adaptation at each dose level. Jumping from 2.5mg directly to 10mg would produce intolerable nausea in most patients.

In practice, the majority of patients stop titrating at 5mg not because they've reached their metabolic ceiling but because prescribers frame 5mg as the standard maintenance dose. It isn't. The clinical trial data shows 5mg as the minimum effective dose for weight reduction. Higher doses produce proportionally greater outcomes without a corresponding increase in serious adverse events. The SURMOUNT-1 trial found that treatment-emergent adverse events leading to discontinuation occurred in 4.3% of patients at 5mg, 7.1% at 10mg, and 6.2% at 15mg. The difference is statistically modest and suggests most patients can tolerate higher doses if titration is gradual.

Here's what real-world maintenance looks like: patients who reach 10mg or 15mg and stabilise there. Meaning weight loss continues at 0.5–1% body weight per week for 12–16 weeks before entering a true plateau phase. Demonstrate the metabolic patterns consistent with therapeutic dosing. Those who stop at 5mg and plateau within eight weeks are undertreated. The signal that you've found your true Mounjaro maintenance dose is sustained metabolic improvement (ongoing weight reduction or stable A1C below 5.7%) without persistent GI symptoms lasting beyond the first month at that dose. If side effects resolve and weight loss stalls, that's a titration signal, not a maintenance endpoint.

Plateau Patterns: When to Increase Your Mounjaro Maintenance Dose

A plateau is not inherently a problem. It's diagnostic information. The question is whether you've plateaued because you've reached your biological ceiling or because the current dose has been fully adapted to and no longer produces the metabolic stress required for continued weight reduction. Tirzepatide works by creating a sustained caloric deficit through appetite suppression and delayed gastric emptying. But the body adapts. Ghrelin rebound occurs, NEAT (non-exercise activity thermogenesis) decreases by 150–250 calories per day, and metabolic rate downregulates in response to sustained weight loss. These adaptations are normal. They don't mean the medication stopped working. They mean the dose is no longer sufficient to overcome the compensatory response.

Here's the pattern that signals undertitration: you've been at 5mg or 7.5mg weekly for eight weeks. Weight loss was consistent for the first four to six weeks. 1–2% body weight reduction weekly. Then flattened completely. Appetite suppression, which was strong initially, has diminished. You're experiencing hunger 90–120 minutes after meals when previously you felt full for four to five hours. Your fasting blood glucose, if you're monitoring it, has crept back up from 85–90 mg/dL to 95–100 mg/dL. These are the markers of receptor adaptation without dose escalation.

The Blunt Honest Answer: if you plateau at 5mg or 7.5mg and still have >15% excess body weight to lose, you haven't found your Mounjaro maintenance dose. You've found the dose where your prescriber stopped titrating. Clinical guidelines recommend continuing dose escalation until one of three endpoints: (1) goal weight achieved and stable for 12 weeks, (2) A1C normalised below 5.7% if diabetic, or (3) persistent GI side effects that don't resolve after eight weeks at the current dose. Anything short of those three conditions means further titration is clinically appropriate. The 15mg ceiling exists not because higher doses are unsafe but because clinical trials didn't test beyond that threshold. It's a regulatory boundary, not a biological one.

Mounjaro Maintenance Dose: Full Comparison

Key Takeaways

• The Mounjaro maintenance dose is individualised and ranges from 5mg to 15mg weekly. It is not a standardised endpoint but the highest dose a patient tolerates while achieving sustained metabolic benefit.
• Clinical trial data from SURMOUNT-1 shows 15mg weekly tirzepatide produced 20.9% mean body weight reduction at 72 weeks compared to 12.9% at 5mg. The dose differential translates to 60% greater weight loss at the therapeutic ceiling.
• Plateauing at 5mg or 7.5mg weekly after six to eight weeks while still carrying >15% excess body weight signals undertitration, not maintenance. True plateau occurs after 16–20 weeks at therapeutic dose.
• GI side effects (nausea, vomiting, diarrhoea) peak during the first four weeks at each new dose level and resolve in 70–80% of patients by week eight. Transient nausea is not a contraindication to further titration.
• Maintenance is defined by three endpoints: goal weight achieved and stable for 12 weeks, A1C normalised below 5.7% if diabetic, or persistent intolerable side effects lasting beyond eight weeks at current dose.

What If: Mounjaro Maintenance Dose Scenarios

What If I Plateau at 5mg Weekly After Two Months?

Increase to 7.5mg after confirming the plateau is real. Defined as less than 0.5% body weight change over four consecutive weeks despite dietary adherence. The plateau likely reflects receptor adaptation rather than dose ceiling, particularly if initial appetite suppression has diminished. Expect renewed nausea for two to three weeks at 7.5mg as GI receptors adapt to the higher dose, followed by resumption of weight loss at 0.8–1.2% weekly if the dose increase was appropriate.

What If I Experience Persistent Nausea at 10mg That Doesn't Resolve After Six Weeks?

Step back to 7.5mg for four weeks, then re-attempt 10mg using a slower meal structure. Smaller portions, lower fat content, and avoiding lying down within two hours of eating. If nausea persists on the second attempt at 10mg beyond eight weeks, 7.5mg becomes your functional maintenance dose. Approximately 15–20% of patients cannot tolerate doses above 7.5mg due to GI sensitivity, and forcing higher doses in this subset produces discontinuation without additional benefit.

What If My A1C Normalised at 7.5mg But I Still Want to Lose More Weight?

Continue titration to 10mg if weight loss has plateaued and you're tolerating 7.5mg without side effects. A1C normalisation is one maintenance endpoint, but it doesn't preclude further dose escalation if additional weight reduction is the clinical goal. The SURMOUNT trials enrolled non-diabetic patients specifically to assess weight loss efficacy independent of glycaemic control. Tirzepatide remains effective for weight management even after metabolic markers normalise.

The Unflinching Truth About Mounjaro Maintenance Dose

Here's the honest answer: most patients on Mounjaro are underdosed. Not because their prescribers are incompetent, but because the standard of care in telehealth weight loss prescribing has coalesced around 5mg as a default maintenance dose when the clinical evidence shows 10mg and 15mg produce meaningfully superior outcomes. The pattern we see repeatedly: patients start at 2.5mg, move to 5mg at week five, experience significant early weight loss, then plateau at week 12–16. The prescriber calls this maintenance. It isn't. It's adaptation without escalation.

The data is unambiguous. Patients who reach 10mg or 15mg weekly lose 50–60% more weight than those who stop at 5mg. The discontinuation rate due to side effects is only marginally higher at therapeutic doses. Meaning the risk-benefit calculation favours titration in the vast majority of cases. The reluctance to escalate stems from outdated prescribing habits carried over from earlier GLP-1 medications like liraglutide, where higher doses did produce disproportionate side effects. Tirzepatide's dual-agonist mechanism doesn't follow that pattern. The dose-response curve is linear and the tolerability ceiling is higher.

If you've plateaued below 10mg and your prescriber won't titrate further without a clear medical contraindication, that's a prescribing gap. Not a medication limitation. The clinical evidence supports continued dose escalation until you reach one of the three true maintenance endpoints: goal weight achieved, A1C normalised, or intolerable persistent side effects. Anything else is settling for partial response when full metabolic reversal was available.

Finding your true Mounjaro maintenance dose isn't about reaching a number on a protocol chart. It's about titrating until the medication delivers the metabolic outcome it was designed to produce. For some patients that happens at 5mg. For most, it requires 10mg or higher. The only way to know is to continue the ladder until you hit the ceiling, not to stop climbing halfway because the first few rungs felt sufficient.